BMRN Q1 2020 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$502M+25.3% YoY

Gross Profit

$391M77.8% margin

Operating Income

$105M20.9% margin

Net Income

$81M16.2% margin

EPS (Diluted)

$0.44

QoQ Revenue Growth

+10.5%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$56M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$4.7B

Total Liabilities

$1.5B

Stockholders' Equity

$3.2B

Cash & Equivalents

$477M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$502M	$401M	+25.3%
Gross Profit	$391M	$312M	+25.4%
Operating Income	$105M	-$54M	+294.5%
Net Income	$81M	-$56M	+244.1%

Revenue Segments

Product

$489M97%

Royalty And Other

$13M3%

Geographic Segments

UNITED STATES

$244M49%

Europe

$145M29%

Latin America

$60M12%

Rest Of World

$53M11%